A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
CompletadoFase 3ClinicalTrials.gov
ID: NCT02510261Tipo: INTERVENTIONALInicio: 16 de jul de 2015Fin estimado: 23 de nov de 2022
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Elegibilidad
Edad mínima: 18 YearsEdad máxima: 85 YearsSexo: ALL
Criterios de inclusión
Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent
Criterios de exclusión
Any new or uncontrolled condition that could make the participant unsuitable for participation
Intervenciones
drug
Patisiran
Patisiran was administered IV.
Ubicaciones
Clinical Trial Site
Buenos Aires, Argentina
Patrocinadores
PrincipalAlnylam Pharmaceuticals
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A Multicenter, Open-Label, Extension Study to Evaluate th... | EligiMed